NEW YORK (GenomeWeb News) – Molecular Detection today said that it has raised $3.3 million through a Series C financing, which it will use to support the launch of its rapid, molecular Staphylococcus aureus test.

In addition to the financing, Molecular Detection said that it has named Todd Wallach to serve as CEO of the firm. Wallach previously was CFO of Aton Pharma and was a VP of finance at Acquity Pharmaceuticals, before that firm was acquired by Opko Health.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.